To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis
Ectycell was established as a subsidiary of Cellectis in September 2009 to research and commercialize industrial uses of products derived from stem cells. Its initial goals are to develop tools for generating induced pluripotent stem (iPS) cells from adult cells, robust and reproducible differentiation of stem cells, and cell libraries for testing drug candidates.
Kyoto University founded the Center for iPS Cell Research and Application (CiRA) as a part of the Institute for Integrated Cell-Material Sciences (iCeMS) in January 2008 to advance induced pluripotent stem (iPS) cell research and applications. It was designated as the university's 14th research institute in April 2010. CiRA is a pioneering organization that specializes in iPS cell research, the world's first research institute of its kind.
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements t
Copyright©2010 PR Newswire.
All rights reserved